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胞和人急性单核白血病细胞进行离体实验分析，采用 MTT 法检测 S-油酰丙醇
胺对细胞活性的影响，和转录激活检测方法检测该化合物对 PPARα 的激活作
用，采用荧光实时定量 PCR 和细胞酶联免疫吸附试验分别检测 VCAM-1、
ICAM-1、 E-选择素的 mRNA 及蛋白水平的表达，同时采用细胞粘附实验检测
其对细胞粘附的影响。实验结果表明，S-油酰丙醇胺在一定程度上可激活
PPARα，可以显著地抑制 VCAM-1 的表达，并呈现出一定的剂量依赖性，但对
ICAM-1、 E-选择素的表达却没有影响，当加入 PPARα 拮抗剂 MK886 时，S-
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Atherosclerosis is a major cause of death from cardiovascular disease in 
industrialized countries. Adhesion of circulating leukocytes to the endothelium is a 
critical early step in atherogenesis. This process depends on the interaction between 
adhesion molecules on the endothelial cell(EC) surface and their cognate ligands on 
leukocytes, these EC adhesion molecules include vascular cell adhesion molecule-1 
(VCAM-1), intercellular adhesion molecule-1 (ICAM-1), E-selectin and P-selectin. 
VCAM-1 and monocytes are associated with chronic inflammation while E-selectin 
with acute inflammation. The development of atherosclerosis is chronic  infl- 
ammation. 
Peroxisome proliferator-activated receptor-alpha (PPARα) is a nuclear receptor 
activated by natural ligands such as fatty acids, and synthetic ligands such as fibrates 
currently used to treat dyslipidemia. PPARα regulates expression of genes encoding 
proteins that involved in lipid metabolism, fatty acid oxidation, and glucose 
homeostasis, by which improve markers for atherosclerosis and insulin resistance. In 
addition, PPARα exerts anti-inflammatory effects both in the vascular wall and the 
liver. PPARα activation interferes with early steps in atherosclerosis by reducing 
leukocyte adhesion to activated endothelial cells of the arterial vessel wall and 
inhibiting subsequent transendothelial leukocyte migration. 
Oleyletheanolamide (OEA) is a naturally occuring lipid that binds with high 
affinity to the PPARα, severs as an endogenous agnoist of PPARα.We synthesized a 
OEA analog: (Z)-(S)-9-octadecenamide, N-(2-hydroxyethyl,1-methy). This study was 
intend to observe antiathe- rosclerotic effects of (Z)-(S)-9-octadecenamide, 
N-(2-hydroxyethyl,1-methy). HUVECs were pretreated with different concentrations 
of (Z)-(S)-9-octadecenamide, N-(2-hydroxyethyl,1-methy), then stimulated with 
tumor necrosis factor(TNF-α) , the expression of ahesion molecules in mRNA and 
protein levels were detected by Real-time PCR and Cell Enzyme linked 
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labeled THP-1cells and analysed by Fluorescened microplate reader. And 
Dual-luciferase reporter assay system was used to determine the effect of 
(Z)-(S)-9-octadecenamide, N-(2-hydroxyethyl,1-methy) on human PPARα activation 
in Hela cells. Results shown that (Z)-(S)-9-octadecenamide, 
N-(2-hydroxyethyl,1-methy) remarkablely activated PPARα, and siginificantly 
inhibited the expression of VCAM-1 at mRNA  and protein levels, but failed to 
inhibit the expression of ICAM-1 and E-selectin. (Z)-(S)-9-octadecenamide, 
N-(2-hydroxyethyl,1-methy) also reduced the aherence of THP-1 cells to 
TNF-a-stimulated HUVECs. (Z)-(S)-9-octadecenamide, N-(2-hydroxyethyl,1-methy) 
can active PPARα  to limit chronic inflammation mediated by VCAM-1 and 
monocytes binding without affecting acute inflammation mediated by E-selectin. 
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1.1.1 PPAR 的发现及分类 
PPAR是过氧化物酶体增殖物激活受体的简称，在此之前人们一直以为PPAR
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成，位于鼠 15 号染色体，人 22 号染色体。和其他核受体类似[10]，PPAR 是由六
个结构域组成的（A-F）（图 1.1）。其中 N 端的 A/B 结构域具有非配体依赖的反
式激活功能（AF-1），该结构域在三种亚型中的保守性比较低，A/B 结构域上还
具有蛋白磷酸化位点；中间的 C 结构域是 DNA 结合域（DNA binging domain），
又称 DBD，它含有两个锌指结构，这样能使受体特异性地结合到靶标 DNA 上，
同时该区域还具有弱的二聚化作用，该区域的序列保守性很高；D 结构域为铰链
区，它连接 DNA 结合域和由 E 域组成的配体结合域；E 结构域组成配体结合域
（Ligand binding domain）又称为 LBD，它具有配体依赖的反式激活功能（AF-2），
AF-2 在对靶标基因的转录调节中起着关键作用，LBD 是激素转录信息的主要传
递者，同时，LBD 是受体发生二聚化的主要部位，而二聚化是受体具备转录激




图 1.1 PPAR 结构域组成 
 
PPAR 通过与其靶基因如酰基辅酶 A 氧化酶（AOX）和脂肪酸结合蛋白的启
动子中的过氧化物酶体增殖剂反应元件（Peroxisome proliferator response 
element，PPRE）结合而发挥转录调控功能（图 1.2）。PPRE 是由两个半位组成，
它们是两个同向重复序列，所以又称为 DR-1 反应元件（Direct Repeat-1 response 
element）。每个半位由序列为 AGGTCA 的六个核苷酸组成，两个半位间相隔一
个核苷酸。PPAR 通过与视黄醛 X 受体（Retinoid X Receptor，RXR）形成异源
二聚体后结合到 PPRE 上，其中的 PPAR 结合在 PPRE 的 5’半位上，RXR 结合在
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